Level-1 Data From the REDUCE Study and the PCPT Data

    October 2015 in “ Prostate Cancer ”
    Goutham Vemana, Gerald L. Andriole
    Studysummary This study found that both finasteride and dutasteride reduced the risk of prostate cancer detection, but finasteride was associated with an increased diagnosis of higher-grade disease, unlike dutasteride.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on sciencedirect.com →
    Discuss this study in the Community →

    Research cited in this study 5

    1. Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor ˜The œJournal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism · 2004
    2. 5alpha-Reductase: History and Clinical Importance PubMed · 2004
    3. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia The New England Journal of Medicine · 2003
    4. 5α-Reductase Activity in the Prostate Urology · 2001
    5. The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia The New England Journal of Medicine · 1998